Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 3, 2021
Product Development
Digging beyond the headlines at AACR 2021
Next-wave strategies for KRAS and TIGIT, allogeneic and personalized cell therapies, and targeted protein degraders
BioCentury | Feb 25, 2021
Deals
Weeks after Pandion’s early clinical readout, Merck pays triple-digit premium in $1.9B takeout
At a 134% premium, pharma gains platform to modulate the immune system
BioCentury | Mar 3, 2020
Finance
Pliant to advance rare fibrosis pipeline with Novartis-led $100M C round
BioCentury | Jan 25, 2020
Tools & Techniques
Manufacturing roundup: Deerfield launches new CDMO, plus a gene/cell therapy JV and more
Biotechs, academics turn to partnerships to overcome manufacturing barriers to gene and cell therapies
BioCentury | Jan 22, 2020
Company News
JV to combine technologies into one gene and cell therapy manufacturing platform
Bio-Techne, Fresenius Kabi and Wilson Wolf will create a platform to scale up manufacturing as Bellicum sells off facility to save costs
BioCentury | Jan 4, 2020
Company News
Next act for BeiGene’s tislelizumab: a Leap deal for gastric cancer
BioCentury | Dec 5, 2019
Tools & Techniques
Using exosomes to switch myeloid cells
Codiak’s exosome therapies against STAT6, CEBPB effectively switch macrophages to kill cancer
BioCentury | Aug 22, 2019
Company News
Aug. 21 Company Quick Takes: GSK, FibroGen take regulatory steps forward for HIF-PH inhibitors in Asia; plus Xtandi, Biotheus/Alligator and more
BioCentury | Jul 11, 2019
Targets & Mechanisms
The tumor stroma rises as the newest source of immuno-oncology targets
Why companies are turning to the tumor stroma to overcome resistance to checkpoint inhibitors
Items per page:
1 - 10 of 90